Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Adma Biologics (ADMA) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $2.0 million.

  • Adma Biologics' Accumulated Depreciation & Amortization rose 526.32% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 526.32%. This contributed to the annual value of $7.7 million for FY2024, which is 131.58% up from last year.
  • As of Q3 2025, Adma Biologics' Accumulated Depreciation & Amortization stood at $2.0 million, which was up 526.32% from $2.0 million recorded in Q2 2025.
  • Adma Biologics' 5-year Accumulated Depreciation & Amortization high stood at $7.7 million for Q4 2024, and its period low was $1.1 million during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $1.9 million (2023), whereas its average is $2.7 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 8333.33% in 2021, then changed by 0.0% in 2024.
  • Adma Biologics' Accumulated Depreciation & Amortization (Quarter) stood at $4.8 million in 2021, then surged by 33.33% to $6.4 million in 2022, then grew by 18.75% to $7.6 million in 2023, then increased by 1.32% to $7.7 million in 2024, then tumbled by 74.03% to $2.0 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $2.0 million for Q3 2025, versus $2.0 million for Q2 2025 and $1.9 million for Q1 2025.